Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00367562 |
Date of registration:
|
22/08/2006 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
|
Scientific title:
|
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy |
Date of first enrolment:
|
January 1996 |
Target sample size:
|
20 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00367562 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
Phase:
|
Phase 4
|
|
Countries of recruitment
|
Argentina
| | | | | | | |
Contacts
|
Name:
|
hernan trimarchi, M.D. |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Hospital Britanico |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- PATIENTES WITH IGA NEPHROPATHY WITH PROTEINURIA OVER 0.5 G/DAY
Exclusion Criteria:
- MALIGNANCY, RENAL FAILURE
Age minimum:
21 Years
Age maximum:
70 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
IGA Nephropathy
|
Intervention(s)
|
Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE
|
Primary Outcome(s)
|
DAILY PROTEINURIA
|
Secondary Outcome(s)
|
RENAL FUNCTION AS ASSESSED BY SERUM CREATININE
|
Secondary ID(s)
|
TEREKOWA33
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|